[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2015010490A - Composicion farmaceutica para el tratamiento de helicobacter pylori. - Google Patents

Composicion farmaceutica para el tratamiento de helicobacter pylori.

Info

Publication number
MX2015010490A
MX2015010490A MX2015010490A MX2015010490A MX2015010490A MX 2015010490 A MX2015010490 A MX 2015010490A MX 2015010490 A MX2015010490 A MX 2015010490A MX 2015010490 A MX2015010490 A MX 2015010490A MX 2015010490 A MX2015010490 A MX 2015010490A
Authority
MX
Mexico
Prior art keywords
treatment
pharmaceutical compositions
helicobacter pylori
pylori
infection
Prior art date
Application number
MX2015010490A
Other languages
English (en)
Other versions
MX368536B (es
Inventor
Reza Fathi
Gilead Raday
Guy Goldberg
Patrick Gosselin
Original Assignee
Redhill Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51297592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015010490(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Redhill Biopharma Ltd filed Critical Redhill Biopharma Ltd
Publication of MX2015010490A publication Critical patent/MX2015010490A/es
Publication of MX368536B publication Critical patent/MX368536B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Se provee una forma de dosificación sólida oral única que comprende una primera composición de dosificación de liberación inmediata que tiene dos agentes antibuióticos y una segunda composición de dosificación de liberación retardada que tiene un inhibidor de la bomba de protones. La forma de dosificación sólida oral única de acuerdo con algunos aspectos de la invención puede usarse para el tratamiento de trastornos asociados con la infección por H. pylori o la prevención de la recurrencia de los trastornos asociados con la infección por H. pylori.
MX2015010490A 2013-02-13 2014-02-12 Composicion farmaceutica para el tratamiento de helicobacter pylori. MX368536B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361764401P 2013-02-13 2013-02-13
US201361764385P 2013-02-13 2013-02-13
PCT/US2014/016071 WO2014127025A1 (en) 2013-02-13 2014-02-12 Pharmaceutical compositions for the treatment of helicobacter pylori

Publications (2)

Publication Number Publication Date
MX2015010490A true MX2015010490A (es) 2015-10-30
MX368536B MX368536B (es) 2019-10-07

Family

ID=51297592

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015010490A MX368536B (es) 2013-02-13 2014-02-12 Composicion farmaceutica para el tratamiento de helicobacter pylori.

Country Status (26)

Country Link
US (8) US9050263B2 (es)
EP (1) EP2956149B1 (es)
JP (1) JP6494529B2 (es)
KR (1) KR102062357B1 (es)
CN (2) CN109893516A (es)
AU (1) AU2014216373B2 (es)
BR (1) BR112015019264B1 (es)
CA (1) CA2900763C (es)
CL (1) CL2015002253A1 (es)
CY (1) CY1122113T1 (es)
DK (1) DK2956149T3 (es)
ES (1) ES2744406T3 (es)
HK (1) HK1217645A1 (es)
HR (1) HRP20191559T1 (es)
HU (1) HUE052411T2 (es)
IL (1) IL240387B (es)
MX (1) MX368536B (es)
NZ (1) NZ711754A (es)
PH (1) PH12015501783A1 (es)
PL (1) PL2956149T3 (es)
PT (1) PT2956149T (es)
RU (1) RU2671400C2 (es)
SG (1) SG11201506318QA (es)
SI (1) SI2956149T1 (es)
UA (1) UA120249C2 (es)
WO (1) WO2014127025A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA120249C2 (uk) 2013-02-13 2019-11-11 Редхілл Байофарма Лтд. Фармацевтичні композиції для лікування від helicobacter pylori
KR101884230B1 (ko) * 2016-02-29 2018-08-01 주식회사 유영제약 에소메프라졸을 포함하는 제제
CN108325054A (zh) * 2017-01-18 2018-07-27 刘泰成 胃肠道感染腔内治疗系统
CA3049033A1 (en) * 2017-10-15 2019-04-18 Centre For Digestive Diseases Compositions and methods for treating, ameliorating and preventing h. pylori infections
CN108497546B (zh) * 2018-03-22 2021-03-19 宝可科技（上海）有限公司 一种烟用添加剂及其制备方法和用途
CN110354125A (zh) * 2019-08-12 2019-10-22 珠海赛隆药业股份有限公司 一种治疗幽门螺杆菌感染的组合物及其制剂和用途
US11878011B2 (en) 2020-05-07 2024-01-23 Redhill Biopharma Ltd. Method for eradicating Helicobacter pylori infection in patients regardless of body mass index
KR20230150745A (ko) * 2022-04-22 2023-10-31 한국생명공학연구원 헬리코박터 파일로리에 의한 위 점막 손상 관련 질환의 예방 또는 치료용 약학적 조성물
CN117398360B (zh) * 2023-12-14 2024-03-15 山东齐都药业有限公司 治疗幽门螺杆菌的复方制剂胶囊及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980637A (en) * 1975-03-17 1976-09-14 Bristol-Myers Company Production of amoxicillin
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
SE9500422D0 (sv) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
WO1998022117A1 (en) 1996-11-22 1998-05-28 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials
SE9700885D0 (sv) 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
AUPP325398A0 (en) * 1998-04-30 1998-05-21 Borody, Thomas J. Improved method for eradicating h. pylori
US5927500A (en) * 1998-06-09 1999-07-27 Milliken & Company Pharmaceutical containment package
JP2000128779A (ja) * 1998-10-20 2000-05-09 Mitsui Chemicals Inc 薬物放出制御型製剤
US20040213847A1 (en) * 2003-04-23 2004-10-28 Matharu Amol Singh Delayed release pharmaceutical compositions containing proton pump inhibitors
WO2005048979A2 (en) * 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
US7981908B2 (en) * 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
EP1803450A1 (en) * 2006-01-03 2007-07-04 Ferrer Internacional, S.A. Pharmaceutical compositions for the eradication of helicobacter pylori
US8383151B2 (en) * 2007-07-06 2013-02-26 Lupin Limited Pharmaceutical compositions of rifaximin
JP5260905B2 (ja) 2007-07-12 2013-08-14 株式会社ジャパンディスプレイ 有機ｅｌ表示装置
WO2009013884A1 (ja) 2007-07-20 2009-01-29 Kowa Co., Ltd. 鉛濃度測定用試薬及び鉛濃度測定方法
EP2192892A2 (en) 2007-07-27 2010-06-09 Depomed, Inc. Pulsatile gastric retentive dosage forms
CN101584681A (zh) * 2008-05-23 2009-11-25 黑龙江福和华星制药集团股份有限公司 一种用于治疗幽门螺旋杆菌感染的片剂胶囊
CN101607086B (zh) * 2009-07-21 2011-11-02 山西安特生物制药股份有限公司 一种复方铋剂组合物及其制备方法
CN102091084B (zh) * 2010-12-09 2012-05-09 王勇 一种复方胶囊及其制备方法
UA120249C2 (uk) * 2013-02-13 2019-11-11 Редхілл Байофарма Лтд. Фармацевтичні композиції для лікування від helicobacter pylori

Also Published As

Publication number Publication date
HRP20191559T1 (hr) 2019-11-29
JP2016508516A (ja) 2016-03-22
US20160235681A1 (en) 2016-08-18
BR112015019264A2 (pt) 2017-07-18
PH12015501783B1 (en) 2015-12-07
JP6494529B2 (ja) 2019-04-03
IL240387A0 (en) 2015-09-24
US20170189341A1 (en) 2017-07-06
CN105163743A (zh) 2015-12-16
US10898439B2 (en) 2021-01-26
RU2671400C2 (ru) 2018-10-31
UA120249C2 (uk) 2019-11-11
PL2956149T3 (pl) 2020-03-31
US11931463B2 (en) 2024-03-19
PH12015501783A1 (en) 2015-12-07
EP2956149A4 (en) 2016-10-12
CA2900763A1 (en) 2014-08-21
BR112015019264A8 (pt) 2019-11-12
NZ711754A (en) 2020-05-29
KR20150118176A (ko) 2015-10-21
US20190175512A1 (en) 2019-06-13
IL240387B (en) 2020-02-27
EP2956149B1 (en) 2019-06-19
KR102062357B1 (ko) 2020-01-03
RU2015138708A (ru) 2017-03-17
BR112015019264B1 (pt) 2021-08-24
CL2015002253A1 (es) 2016-07-29
PT2956149T (pt) 2019-09-20
US11135172B2 (en) 2021-10-05
US20220062188A1 (en) 2022-03-03
HK1217645A1 (zh) 2017-01-20
SG11201506318QA (en) 2015-09-29
CN109893516A (zh) 2019-06-18
CA2900763C (en) 2021-04-06
AU2014216373A1 (en) 2015-08-27
AU2014216373B2 (en) 2017-12-21
DK2956149T3 (da) 2019-09-09
US10238606B2 (en) 2019-03-26
US20140227353A1 (en) 2014-08-14
US20150044283A1 (en) 2015-02-12
CY1122113T1 (el) 2020-11-25
US20190336451A1 (en) 2019-11-07
US9603806B2 (en) 2017-03-28
US9498445B2 (en) 2016-11-22
WO2014127025A1 (en) 2014-08-21
US20240325313A1 (en) 2024-10-03
ES2744406T3 (es) 2020-02-25
HUE052411T2 (hu) 2021-04-28
EP2956149A1 (en) 2015-12-23
SI2956149T1 (sl) 2019-11-29
US9050263B2 (en) 2015-06-09
MX368536B (es) 2019-10-07

Similar Documents

Publication Publication Date Title
PH12015501783B1 (en) Pharmaceutical compositions for the treatment of helicobacter pylori
MY196173A (en) Cot Modulators And Methods Of Use Thereof
MX2018001990A (es) Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac.
PH12016501790B1 (en) Pharmaceutical compositions of therapeutically active compounds
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
PH12016500024A1 (en) Bromodomain inhibitor
MX2013000567A (es) Composiciones farmaceuticas de moduladores de c-met.
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
WO2011113013A3 (en) Methods and compositions for treating viral or virally-induced conditions
PH12016501122A1 (en) Delayed release compositions of linaclotide
PH12015501096A1 (en) Composition for immediate and extended release
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
MX2015012318A (es) Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2015010486A (es) Composicion masticable para administracion oral y proceso para preparar la misma.
MX2016016039A (es) Formulacion farmaceutica para reducir la frecuencia de micción y método para su utilización..
MX2015015537A (es) Formulacion de pastillas de nicotina.
WO2014065640A3 (ko) 외톨개모자반 추출물 또는 이의 분획물을 유효성분으로 함유하는 염증성 질환 치료 또는 예방용 조성물
EA201270547A1 (ru) Фармацевтическая композиция
IN2013MU03309A (es)
IN2013MU03422A (es)
IN2013MU03308A (es)
IN2013MU03428A (es)
TN2010000445A1 (en) Oral and injectable formulations of tetracycline compounds

Legal Events

Date Code Title Description
FG Grant or registration